Pharma

Gilead expected to submit US antitrust filing for CymaBay Therapeutics acquisition over “next couple of weeks”

American biopharmaceutical company Gilead should file for US antitrust approval for its proposed acquisition of liver disease drug specialist CymaBay Therapeutics in the “next couple of weeks”, Equity Report has learned. According to a person […]

Gilead expected to submit US antitrust filing for CymaBay Therapeutics acquisition over “next couple of weeks” Read More »

Dechra rivals unlikely to raise major concerns over EQT-led takeover in ongoing EC antitrust review

Competitors of British animal health products supplier Dechra Pharmaceuticals are not expected to oppose a planned takeover of the company by a consortium led by Swedish private equity firm EQT, a Brussels-based antitrust lawyer who

Dechra rivals unlikely to raise major concerns over EQT-led takeover in ongoing EC antitrust review Read More »

Abcam founder’s activist campaign draws attention to shareholder rights at European pharma companies with a US listing

UK-based protein research tools company Abcam has attracted interest from “pure-play” lab tools providers, as well as pharma companies with a broader offering, a person briefed on the process told Equity Report. Last month, the

Abcam founder’s activist campaign draws attention to shareholder rights at European pharma companies with a US listing Read More »

Changes to China’s Anti-Monopoly Law slowing down merger review process, local lawyers say

Merger control reviews by China’s State Administration for Market Regulation (SAMR) are facing significant delays, even under the fast-track procedure, partly due to the recent amendments to China’s Anti-Monopoly Law, local antitrust lawyers told Equ…

Changes to China’s Anti-Monopoly Law slowing down merger review process, local lawyers say Read More »

Carl Icahn launches “referendum” on Illumina’s direction, US shareholder activism lawyer says

By proposing three alternative candidates for election to the nine-member board of directors of US life science company Illumina, shareholder Carl Icahn has launched a “referendum” on the company’s direction, a US lawyer with expertise

Carl Icahn launches “referendum” on Illumina’s direction, US shareholder activism lawyer says Read More »

error: Content is protected !!
Scroll to Top
Scroll to Top

Valeria Camerino

Valeria is a seasoned business and financial journalist with fifteen years of industry experience.

Before launching Equity Report in October 2022, Valeria was European Editor for US-based financial news service CTFN, where she spent seven years reporting on event-driven situations, breaking news stories on complex financial and regulatory issues across several jurisdictions, from Europe and Africa to China, India, Brazil, and Australia.

Prior to that, she was Senior Reporter at TelecomFinance, Middle East correspondent, and later Southern Europe correspondent at Mergermarket (currently ION), and held a number of editorial positions with Dubai and London-based b2b publications.

She holds a BA (Hons) in Languages and Public Relations from Leeds Beckett University and an MA in International Journalism from University of Central Lancashire.